Hydroxyurea-induced foot ulcer successfully treated with a topical basic fibroblast growth factor product.
Aragane
Y
Y
Okamoto
T
T
Yajima
A
A
Isogai
R
R
Kawada
A
A
Tezuka
T
T
D000287:Administration, Topical; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology; D005346:Fibroblast Growth Factors / Q000008:administration & dosage*; D016523:Foot Ulcer / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D005346:Fibroblast Growth Factors; D006918:Hydroxyurea